KR-20260065762-A - Companion diagnostic kit for predicting the astragalin treatment response of inflammatory bowel disease
Abstract
The present invention relates to a companion diagnostic kit for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease. By confirming that the expression of stathmin or RCC2 (regulator of chromosome condensation 2) is specifically reduced in a responder group that is responsive to Astragalin treatment for inflammatory bowel disease, the kit can be usefully utilized as a companion diagnostic tool for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease.
Inventors
- 한유민
Assignees
- 서울대학교병원
Dates
- Publication Date
- 20260511
- Application Date
- 20260410
- Priority Date
- 20230208
Claims (4)
- A companion diagnostic kit for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease, comprising as an active ingredient a composition for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease, comprising a preparation capable of confirming the expression level of stathmin or RCC2 (regulator of chromosome condensation 2) protein or a gene encoding therefrom.
- A companion diagnostic kit according to claim 1, characterized in that the expression of the protein or the gene encoding it is specifically reduced in a response group responsive to astragalin treatment for inflammatory bowel disease.
- A companion diagnostic kit according to claim 1, characterized in that the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
- A companion diagnostic kit according to claim 1, wherein the preparation capable of confirming the expression level is an antibody, peptide, aptamer, or compound that specifically binds to the protein; or a primer or probe that specifically binds to the gene encoding the protein.
Description
Companion diagnostic kit for predicting the astragalin treatment response of inflammatory bowel disease The present invention relates to a companion diagnostic kit for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease and is a chronic, recurrent inflammatory disease of the gastrointestinal tract. Due to the recent Westernization of lifestyles, the incidence of inflammatory bowel disease in Korea has been continuously increasing, leading to a significant increase in the socioeconomic burden. The advancement of high-throughput molecular biological analysis technologies and the dramatic improvement in information processing capabilities have enabled holistic and integrated analysis using proteomics. Analysis, which was previously limited to a few specimens such as blood and urine, has recently expanded to include a diverse range of specimens such as tissues, tears, and mucus. Due to the varying degrees of morphological, molecular, and proteomic heterogeneity found in different tissues, there is a growing demand for the analysis of colon tissue, which is directly affected by inflammatory bowel disease. Figure 1 shows an experimental overview of a mouse model of dextran sulfate sodium (DSS)-induced colitis. Figure 2 is a flowchart of the quantitative proteomic analysis of a mouse model of colitis. Figure 3 shows the colitis mouse model groups and the number of individuals per group used for quantitative proteomic analysis. Figure 4 shows the results of SWATH-MS analysis on colon tissue of a mouse model of colitis and the interrelationships between samples. Figure 5 is a Venn diagram of the qualitative proteins for each experimental group of the colitis mouse model. Figure 6 shows the results of the principal component analysis for a mouse model of colitis. Figure 7 shows the PC2-associated protein factor identified through principal component analysis of a mouse model of colitis. Figure 8 shows the results of gene ontology analysis on proteins whose expression increased or decreased in the Astragalin 2 mg treatment group compared to the positive control group (PC). Figure 9 shows the results confirming that the expression of stathmin was reduced in the astragalin-treated group compared to the positive control group (PC). Figure 10 shows the results confirming that the expression of RCC2 (regulator of chromosome condensation 2) was reduced in the Astragalin-treated group compared to the positive control group (PC). The present invention will be described in more detail below. The present invention provides a biomarker composition for companion diagnostics to predict the responsiveness to Astragalin treatment for inflammatory bowel disease, comprising as an active ingredient stathmin or RCC2 (regulator of chromosome condensation 2) protein or a gene encoding the same. The aforementioned stathmin is known to be a protein involved in the hepatocyte growth factor signaling mechanism and to perform negative regulation of stress fiber assembly. The above RCC2 (regulator of chromosome condensation 2) is known to be a protein involved in the cell cycle and cell division, and performs negative regulation of integrin-mediated signaling and focal adhesion assembly. The above protein or the gene encoding it may be specifically reduced in the response group responsive to astragalin treatment for inflammatory bowel disease. The above-mentioned inflammatory bowel disease may be ulcerative colitis or Crohn's disease, but is not limited thereto. In the present invention, "Companion Diagnosis" refers to a diagnostic technique for predicting in advance a patient's responsiveness to a specific drug treatment. In the present invention, "biomarker for companion diagnosis" refers to an indicator for predicting a patient's responsiveness to a specific drug treatment in advance, and may include proteins, DNA, RNA, metabolites, etc. That is, regarding a specific disease, it refers to a marker that can distinguish between normal and pathological states, predict treatment response, and be objectively measurable. In addition, the present invention provides a companion diagnostic composition for predicting the responsiveness to Astragalin treatment for inflammatory bowel disease, comprising a preparation capable of confirming the expression level of stathmin or RCC2 (regulator of chromosome condensation 2) protein or the gene encoding it. The preparation capable of confirming the above expression level may be an antibody, peptide, aptamer, or compound that specifically binds to the protein; or a primer or probe that specifically binds to the gene encoding the protein, but is not limited thereto. In the present invention, “primer” refers to a short nucleic acid sequence having a short free 3’ hydroxyl group, capable of forming base pairs with a complementary template, and functioning as a starting point for template strand replication